Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD di Fletcher, RA, Herrington, WG, Agarwal, R, Mayne, KJ, Arnott, C, Jardine, MJ, Mahaffey, KW, Perkovic, V, Staplin, N, Wheeler, DC, Chertow, GM, Heerspink, HJL, Neuen, BL

Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis di Patel, SM, Kang, YM, Im, K, Neuen, BL, Anker, SD, Bhatt, DL, Butler, J, Cherney, DZI, Claggett, BL, Fletcher, RA, Herrington, WG, Inzucchi, SE, Jardine, MJ, Mahaffey, KW, McGuire, DK, McMurray, JJV, Neal, B, Packer, M, Perkovic, V, Solomon, SD, Staplin, N, Vaduganathan, M, Wanner, C, Wheeler, DC, Zannad, F, Zhao, Y, Heerspink, HJL, Sabatine, MS, Wiviott, SD

2017 cardiovascular and stroke endpoint definitions for clinical trials di Hicks, KA, Mahaffey, KW, Mehran, R, Nissen, SE, Wiviott, SD, Dunn, B, Solomon, SD, Marler, JR, Teerlink, JR, Farb, A, Morrow, DA, Targum, SL, Sila, CA, Hai, MT, Jaff, MR, Joffe, HV, Cutlip, DE, Desai, AS, Lewis, EF, Gibson, CM, Landray, MJ, Lincoff, AM, White, CJ, Brooks, SS, Rosenfield, K, Domanski, MJ, Lansky, AJ, McMurray, JJV, Tcheng, JE, Steinhubl, SR, Burton, P, Mauri, L, O'Connor, CM, Pfeffer, MA, Hung, HMJ, Stockbridge, NL, Chaitman, BR, Temple, RJ

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials di Hicks, KA, Mahaffey, KW, Mehran, R, Nissen, SE, Wiviott, SD, Dunn, B, Solomon, SD, Marler, JR, Teerlink, JR, Farb, A, Morrow, DA, Targum, SL, Sila, CA, Hai, MTT, Jaff, MR, Joffe, HV, Cutlip, DE, Desai, AS, Lewis, EF, Gibson, CM, Landray, MJ, Lincoff, AM, White, CJ, Brooks, SS, Rosenfield, K, Domanski, MJ, Lansky, AJ, McMurray, JJV, Tcheng, JE, Steinhubl, SR, Burton, P, Mauri, L, O'Connor, CM, Pfeffer, MA, Hung, HMJ, Stockbridge, NL, Chaitman, BR, Temple, RJ, Standardized Data Collection For Cardiovascular Trials Initiative (Scti)